Skip to main content

Advertisement

Table 4 Genes the expression levels of which differed between untreated patients with polymyalgia rheumaticaand untreated controls (FD), and which responded to prednisolone treatment in the patients (FC) (44 genes)

From: Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment

Gene symbol Gene name FDa p FCb p
BDNF brain-derived neurotrophic factor +1.8 0.016 −3.1 0.001
SVIP small VCP/p97-interacting protein +1.7 0.002 −1.7 0.004
TM4SF18 transmembrane 4 L six family member 18 +1.5 0.007 −1.3 0.033
TMTC1 transmembrane and tetratricopeptide repeat containing 1 +1.5 0.001 −1.5 0.003
TMEM18 transmembrane protein 18 +1.5 0.008 −1.4 0.028
N4BP2L1 NEDD4 binding protein 2-like 1 +1.5 0.019 −1.4 0.033
FMO2 flavin containing monooxygenase 2 (non-functional) +1.5 0.002 −1.4 0.012
RPL37 ribosomal protein L37 +1.5 <0.001 −1.5 <0.001
FAM184B family with sequence similarity 184, member B +1.4 0.013 −1.3 0.042
LOC100507303 uncharacterized LOC100507303 +1.4 0.019 −1.6 0.004
RNF114 ring finger protein 114 +1.3 0.016 −1.3 0.030
RERE arginine-glutamic acid dipeptide (RE) repeats +1.3 0.003 −1.3 0.008
TUBD1 tubulin, delta 1 +1.3 0.003 −1.4 0.003
ZNF195 zinc finger protein 195 +1.3 0.003 −1.3 0.002
DFFA DNA fragmentation factor, 45 kDa, alpha polypeptide +1.3 0.010 −1.2 0.016
RBBP6 retinoblastoma binding protein 6 +1.3 0.004 −1.2 0.025
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin) +1.3 0.011 −1.2 0.022
EIF4B eukaryotic translation initiation factor 4B +1.3 0.017 −1.3 0.015
RSBN1 round spermatid basic protein 1 +1.2 0.003 −1.2 0.016
PSIP1 PC4 and SFRS1 interacting protein 1 +1.2 0.010 −1.3 0.007
EIF3G eukaryotic translation initiation factor 3, subunit G +1.2 0.006 −1.3 0.005
PXDC1 PX domain containing 1 +1.2 0.042 +1.5 0.014
BCKDHA branched chain keto acid dehydrogenase E1, alpha polypeptide +1.2 0.024 −1.4 0.004
AKR7A2 aldo-keto reductase family 7, member A2 +1.2 0.010 −1.2 0.002
MRPS2 mitochondrial ribosomal protein S2 +1.2 0.018 −1.3 0.006
RORA RAR-related orphan receptor A +1.2 0.049 −1.2 0.044
RPL36AL ribosomal protein L36a-like +1.2 0.011 −1.2 0.008
PAQR9 progestin and adipoQ receptor family member IX −2.0 <0.001 +1.4 0.027
FAM69A family with sequence similarity 69, member A −1.8 0.001 +1.7 <0.001
TP53INP2 tumor protein p53 inducible nuclear protein 2 −1.8 <0.001 +1.3 0.017
SH3KBP1 SH3-domain kinase binding protein 1 −1.8 0.002 +1.3 0.035
NINJ2 ninjurin 2 −1.7 0.039 +2.3 0.002
MEST mesoderm specific transcript homolog (mouse) −1.7 0.010 +2.7 0.049
ITGB1BP2 integrin beta 1 binding protein (melusin) 2 −1.6 <0.001 +1.5 0.003
BPGM 2,3-bisphosphoglycerate mutase −1.5 <0.001 +1.2 0.036
MTFP1 mitochondrial fission process 1 −1.5 0.004 +1.3 0.017
MAP2K3 mitogen-activated protein kinase kinase 3 −1.5 0.003 +1.3 0.021
LRRN4CL LRRN4 C-terminal like −1.4 0.042 +1.5 0.006
FBXO9 F-box protein 9 −1.4 <0.001 +1.3 0.001
JARID2 jumonji, AT rich interactive domain 2 −1.4 <0.001 +1.3 0.007
PRSS23 protease, serine, 23 −1.4 0.030 +1.5 0.022
OLFML2B olfactomedin-like 2B −1.4 0.049 +1.7 0.031
MEMO1 mediator of cell motility 1 −1.3 0.004 +1.3 0.012
  1. FD fold difference, FC fold change
  2. a + and −; expression levels were higher and lower, respectively, in patients with polymyalgia rheumatica than in controls before treatment with prednisolone
  3. b + and −; expression levels increased and decreased, respectively, in patients with polymyalgia rheumatica after treatment with prednisolone
  4. Entry in bold indicates that the gene also responded significantly to prednisolone in controls. The response in controls for the RORA gene was of the same magnitude as in patients but in the opposite direction